Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGB101 in MCI due to AD (HOPE4MCI)
NCT03486938Phase 3Completed
- Sponsor
- AgeneBio
- Start
- Dec 2018
- Primary completion
- Nov 2022
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of levetiracetam in mild cognitive impairment due to Alzheimer's disease, sponsored by AgeneBio. Started Dec 2018; status: completed.
02
Drugs
levetiracetam
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on NCT03486938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486938.